The anticompetitive regulator, Superintendency of Industry and Commerce, claims Pfizer sold several of its medicines at a price ranging from 4 percent to 651 percent above the agreed-upon amount between July 2016 and December 2016.
The agency claims that Pfizer sold its ophthalmic solution Xalatan for about $33 a unit, when the agency set the price at $4. Additionally, Pfizer’s antidepressant Effexor was sold 348 percent above the official price, according to the regulators.
A Pfizer spokesperson denied the allegations and told STAT the company was complying with the regulator’s investigation.
The move comes as a growing number of countries worldwide are attempting to curb the rising costs of prescription drugs.
Access the full report here.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Average chief pharmacy officer salary by state